The Inflammation Network

Globally, 3 out of 5 persons lose their lives to chronic inflammatory conditions, such as diabetes, cardiovascular disorders, cancer, chronic respiratory diseases, skin diseases, renal diseases and obesity. Inflammatory diseases are the most prevailing cause of death worldwide and the numbers keep rising.

The network focuses on reducing the burden of infectious and inflammatory diseases caused by pathogens, damaged cells, toxic compounds or radiation in order to develop new diagnostic and treatment technologies.

As a society, we need more knowledge about the correlation between e.g. inflammation and development of cancer, about biomarkers and about molecular mechanisms of autoimmunity in e.g. rheumatological conditions - not to mention chronic mucosal inflammation. In the inflammation network we collaborate interdisciplinarily in order to find answers.

We comprise a wide range of researchers with interest in diagnostic methods, epidemiological data, inflammatory markers and intracellular pathways, understanding of cell population and tissue structures, among others.

Paper of the Month

Rikke Nørregaard

Chronic kidney disease (CKD) affects approximately 10% of the adult population worldwide and is characterized by the development of renal injury and fibrosis and progressive loss of renal function, ultimately CKD leads to end-stage renal disease (ESRD). The incidence and prevalence of CKD has been increasing concurrently with the increase in lifestyle diseases such as diabetes, hypertension, obesity and longer lifespan.

It is now recognized that CKD is not always progressive, but that regression of albuminuria and improvement in renal function can occur if the injurious stimulus is removed. However, the cellular and molecular pathways mediating injury regression are poorly understood, partly because renal biopsies are rarely performed in patients who are clinically improving.

This paper shows that the innate immune system is central to injury and repair in the kidney and describe the heterogeneity of myeloid cell subsets behind these processes. Using complementary technologies, including bulk tissue transcriptomics, integrated droplet– and plate-based single-cell RNA sequencing, and paired blood exchange, the authors resolved myeloid cell heterogeneity in a murine model of reversible unilateral ureteral obstruction by creating a single-cell atlas.

Taken together this paper identifies novel myeloid subtypes, based on transcriptomics in single cells, that represent therapeutic targets to inhibit progression or promote regression of kidney disease.

Conway et al.: Kidney single-cell atlas reveals myloid heterogeneity in progression and regression of kidney disease

Annual meeting

The first annual meeting will be held on 11 November 2021 in the AIAS Auditorium (1632-201).

Contact us for more information

Anja P. Einholm

Network Coordinator